SCA
CTSO icon

Stonebridge Capital Advisors’s Cytosorbents Corp CTSO Stock Holding History

Stonebridge Capital Advisors’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,000
Closed -$3K – 932
2022
Q1 		$3K Hold
1,000
– – ﹤0.01% 837
2021
Q4 		$4K Hold
1,000
– – ﹤0.01% 765
2021
Q3 		$8K Sell
1,000
-1,000
-50% -$8.12K ﹤0.01% 645
2021
Q2 		$17K Buy
2,000
+1,000
+100% +$8.43K ﹤0.01% 649
2021
Q1 		$9K Buy
+1,000
New +$9.53K ﹤0.01% 648

Other funds holding CTSO

SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stonebridge Capital Advisors's CTSO Position: Q2 2022 in Review

Stonebridge Capital Advisors sold out of Cytosorbents Corp (CTSO) in Q2 2022, closing a stake of 1,000 shares — an estimated $3K sold.

Stonebridge Capital Advisors first reported a position in CTSO in Q1 2021 and held it in 5 quarters. The position peaked at $17K in Q2 2021. 78 funds tracked by Wall St. Rank hold CTSO as of Q2 2022.

  • Stonebridge Capital Advisors reported no remaining Cytosorbents Corp position as of Q2 2022 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 1,000 Cytosorbents Corp shares in Q2 2022, an estimated $3K.
  • Stonebridge Capital Advisors first reported a position in Cytosorbents Corp in Q1 2021 and held it in 5 quarters.
  • Stonebridge Capital Advisors's Cytosorbents Corp position peaked at $17K in Q2 2021.
  • 78 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2022.

Based on Stonebridge Capital Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.